Show simple item record

dc.date.accessioned2021-03-08T19:31:58Z
dc.date.available2021-03-08T19:31:58Z
dc.date.issued2020-11-24
dc.identifier.urihttps://hdl.handle.net/11244/329017
dc.description.abstractHighly antigenic yet safe vaccines against diseases caused by Paramyxoviridae viruses such as respiratory syncytial virus (RSV) are provided. The vaccines comprise attenuated Paramyxoviridae viruses with high antigenicity but which display impaired cell-to-cell transmission as a result of genetic manipulation of the gene encoding the matrix (M) protein. In the viruses, the M protein is absent or mutated to a less active form. Screening or assay systems and methods for evaluating the infectivity of mutant M proteins and for identifying suitable M candidates for live-attenuated vaccine virus and VLP production, are also provided.
dc.formatapplication/pdf
dc.format.extent61 pages
dc.languageen_US
dc.publisherU.S. Patent and Trademark Office
dc.titleEngineered respiratory syncytial viruses with control of cell-to-cell virus transmission for enhanced safety of live virus vaccines
dc.typeText
osu.filenamepat10844357.pdf
osu.accesstypeOpen Access
dc.type.genrePatent
dc.contributor.inventorOomens, Antonius G. P.
dc.identifier.patentID10844357
dc.date.filed2011-06-01
dc.contributor.assigneeBoard of Regents/Oklahoma State University and the A & M Colleges
dc.subject.cpcclassesC07K 14/005 (20130101)
dc.subject.cpcclassesC12N 7/00 (20130101)
dc.subject.cpcclassesC12Q 1/06 (20130101)
dc.subject.cpcclassesA61K 2039/5254 (20130101)
dc.subject.cpcclassesC12N 2760/18562 (20130101)
dc.subject.cpcclassesC12N 2760/18511 (20130101)
dc.subject.cpcclassesA61K 2039/5258 (20130101)
dc.subject.cpcclassesC12N 2760/18522 (20130101)
dc.subject.cpcclassesC12N 2760/18534 (20130101)
dc.subject.cpcclassesG01N 2333/115 (20130101)
dc.subject.cpcclassesC12N 2760/18523 (20130101)
dc.subject.cpcclassesG01N 2500/00 (20130101)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record